Mastodawn

𝗖𝗮𝗻 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿𝘀 𝗺𝗮𝗸𝗲 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗺𝗼𝗿𝗲 𝗮𝗳𝗳𝗼𝗿𝗱𝗮𝗯𝗹𝗲?
Governments like South Korea are introducing pricing caps on 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿𝘀, 𝗶𝗺𝗽𝗿𝗼𝘃𝗶𝗻𝗴 𝗮𝗰𝗰𝗲𝘀𝘀𝗶𝗯𝗶𝗹𝗶𝘁𝘆 𝗮𝗻𝗱 𝗯𝗼𝗼𝘀𝘁𝗶𝗻𝗴 𝗮𝗱𝗼𝗽𝘁𝗶𝗼𝗻 across APAC.
𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://www.kenresearch.com/industry-reports/asia-pacific-biopharmaceuticals-market?utm_source=Mastadon&utm_medium=Social&utm_campaign=Aniket

Asia Pacific Biopharmaceuticals Market Analysis and Outlook

Discover the future of Asia Pacific Biopharmaceuticals Market, size at USD 44 billion in 2025, showcasing demand trends and future opportunities.

Biostock Feb 5

Alvotech Reports Positive PK Results for AVT80

Alvotech has announced top-line results from a pivotal pharmacokinetic study of AVT80, a proposed biosimilar to Entyvio (vedolizumab). The randomized, double-blind, 3-arm study assessed PK similarity, safety, and immunogenicity in healthy adults after a single 108 mg/0.68 mL subcutaneous injection. The data supports the development of the candidate for patients worldwide.

#Alvotech #biosimilars #biotech #lifescience

Yonhap Infomax News Feb 5

Celltrion Co. posts record 2025 results, surpassing 4 trillion won in revenue and 1 trillion won in operating profit, driven by high-margin new biosimilars and robust global sales.
#YonhapInfomax #Celltrion #OperatingProfit #Biosimilars #GlobalSales #RevenueGrowth #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=103936

Celltrion Opens Era of 4 Trillion Won in Annual Revenue and 1 Trillion Won in Operating Profit Last Year (Comprehensive)

Celltrion Co. posts record 2025 results, surpassing 4 trillion won in revenue and 1 trillion won in operating profit, driven by high-margin new biosimilars and robust global sales.

Yonhap Infomax

Biostock Jan 29

Alvotech Secures Global Settlement for Aflibercept Biosimilar

Alvotech reached a settlement to market its biosimilar globally. Entry starts Jan 1, 2026, in the UK and Canada. The EEA and other regions follow May 1, 2026. Japan allows full indications by Nov 1, 2026. Combined with a US Q4 2026 license, the company secures worldwide rights to supply partners, subject to regulatory approval.

Yonhap Infomax News Jan 2

Celltrion Group Chairman Seo Jung-jin announced a three-year AI-driven innovation plan through 2028, aiming for a quantum leap in biosimilars, digital healthcare, and global expansion.
#YonhapInfomax #Celltrion #SeoJungJin #ArtificialIntelligence #Biosimilars #DigitalHealthcare #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=98140

Celltrion Chairman Seo Jung-jin Vows 'AI-Driven Transformation—Three Years of Innovation for a Quantum Leap'

Celltrion Group Chairman Seo Jung-jin announced a three-year AI-driven innovation plan through 2028, aiming for a quantum leap in biosimilars, digital healthcare, and global expansion.

Yonhap Infomax

Yonhap Infomax News Dec 30

Korea Biomedicine Industry Association Chairman Lee Jeong-seok highlighted 2025 as a year of transition and restructuring for the bio industry, projecting significant growth and global competitiveness in the coming year through advances in AI drug development, biosimilars, and CDMO.
#YonhapInfomax #KoreaBiomedicineIndustryAssociation #Biopharmaceutical #AIDrugDevelopment #Biosimilars #CDMO #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=97657

Korea Biomedicine Industry Association Chief - 'A Year of Transition and Restructuring—Poised for Leap Forward in the New Year'

Korea Biomedicine Industry Association Chairman Lee Jeong-seok highlighted 2025 as a year of transition and restructuring for the bio industry, projecting significant growth and global competitiveness in the coming year through advances in AI drug development, biosimilars, and CDMO.

Yonhap Infomax

Yonhap Infomax News Nov 25

Samsung Bioepis has promoted two Executive Vice Presidents and four Senior Vice Presidents in a performance-based leadership reshuffle, highlighting expertise in clinical development, manufacturing, regulatory affairs, and business strategy.
#YonhapInfomax #SamsungBioepis #ExecutivePromotion #Biosimilars #ClinicalDevelopment #BusinessStrategy #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=92338

Samsung Bioepis Promotes Two Executive Vice Presidents in Leadership Reshuffle

Samsung Bioepis has promoted two Executive Vice Presidents and four Senior Vice Presidents in a performance-based leadership reshuffle, highlighting expertise in clinical development, manufacturing, regulatory affairs, and business strategy.

Yonhap Infomax

Yonhap Infomax News Nov 5

Daewoong Pharmaceutical Co. is accelerating global expansion by showcasing its microneedle drug delivery and biosimilar technologies at CPHI Worldwide, securing new partnerships and boosting API exports.
#YonhapInfomax #DaewoongPharmaceutical #MicroneedleTechnology #Biosimilars #CPHIWorldwide #APIExports #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=89249

Daewoong Pharmaceutical Expands Global Partnerships in Microneedle and Biosimilar Technologies

Daewoong Pharmaceutical Co. is accelerating global expansion by showcasing its microneedle drug delivery and biosimilar technologies at CPHI Worldwide, securing new partnerships and boosting API exports.

Yonhap Infomax

Vietnamnet BOT Oct 29

Nearly 70% of cancer patients face financial crises within one year after leaving hospital, highlighting urgent need for support. Hospital K suggests using biosimilars to reduce costs and improve treatment access.

#cancercare #financialcrisis #healthpolicy #access2medicine #unreadyposts #VietnamHealth #SustainableHealthcare #biosimilars #patientrights #VietnamNet

#ungthư #sứckhỏe #chínhsách y tế #khủnghoảngtàichính #dượcphẩmsinhhọc #tiếpcậnđiềutrị #bệnhviệnK #côngbằngy tế #sốngkhỏemạnh #vietn

Divantis Aug 10, 2025

Wachstumsstarker Bereich treibt die Marge – Aktienkurs verdoppelt

Gute 2 Jahre ist dieser Spin-off aus dem Pharmasektor nun an der Börse. Abgespalten von vom Schweizer Novartis-Konzern hatten damals die Aktionäre die Aktien zusätzlich in ihr Depot gebucht bekommen.

Ich fand das Geschäft mit Generika schon damals interessant und entschied mich, die Aktien im Depot zu behalten. Und ich war so überzeugt, dass ich sogar meine Novartis-Position noch erhöhte, um mehr vom Spin-off abzubekommen.

Nun ist es Zeit für eine erste Zwischenbilanz. Und die kann sich sehen lassen: der Aktienkurs hat sich innerhalb dieser 2 Jahre nahezu verdoppelt.

Und so ist aus dem dreistelligen Investment mittlerweile ein vierstelliger Depotwert geworden.

Wie ich die weiteren Perspektiven einschätze, erfährst Du in diesem Beitrag.

[…]

https://www.divantis.de/wachstumsstarker-bereich-treibt-die-marge-aktienkurs-verdoppelt/